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Summary
Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unex-
pected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition
of these receptors. Here we describe the 2.8 Å resolution X-ray crystal structure of the antigen binding (Fab) fragment
from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR
(sEGFR). The sEGFR is in the characteristic “autoinhibited” or “tethered” inactive configuration. Cetuximab interacts ex-
clusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing
the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects
contribute to potent inhibition of EGFR activation.S I G N I F I C A N C E
Members of the EGFR family are implicated in many human cancers and are the targets of several anticancer therapies. The anti-
ErbB2 (HER2/Neu) antibody trastuzumab (Herceptin) is well established as a key element in treatment of metastatic ErbB2-positive
breast cancers. In 2004, the anti-EGFR antibody cetuximab (Erbitux) was approved for treatment of advanced colorectal cancer. By
contrast with trastuzumab, which does not prevent ligand-induced ErbB receptor activation, the primary mechanism of cetuximab is
to block ligand-stimulated EGFR signaling. Our structure of sEGFR in complex with the antigen binding fragment of cetuximab reveals
the molecular mechanism of its inhibition of ligand-induced EGFR dimerization and activation, and has important implications for
the development of new strategies to target EGFR-positive cancers.Introduction
Ligand-induced signaling from receptor tyrosine kinases (RTKs)
of the epidermal growth factor receptor (EGFR) family (also
known as ErbB or HER) regulates many cellular processes, in-
cluding proliferation, cell motility, and differentiation (Holbro
and Hynes, 2004). Perturbations in these cellular signals can
lead to malignant transformation, and the correlation between
EGFR and cancer has been firmly established (Arteaga, 2003;
Mendelsohn and Baselga, 2003). Deregulation of EGFR can
arise from its overexpression (Arteaga, 2002), mutation/trunca-
tion of the receptor (Boerner et al., 2003), or activation by aber-
rant autocrine growth factor loops (Normanno et al., 2001).
EGFR has been implicated in the development of a wide range
of epithelial cancers, including those of the breast, colon, head
and neck, kidney, lung, pancreas, and prostate. In these set-
tings, deregulation of EGFR correlates with decreased disease-
free and overall survival (Gullick, 1991; Klijn et al., 1992; Sains-
bury et al., 1985; Salomon et al., 1995). In the early 1980s, as
details of the normal and oncogenic properties of EGFR were
unfolding, it was proposed that EGFR signaling and cellular
proliferation could be blocked by antibodies that interact withCANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCthe extracellular region of EGFR, and prevent the binding of
activating ligands: EGF, transforming growth factor α (TGFα),
amphiregulin (AR), betacellulin (BTC), epigen (EPN), epiregulin
(EPR), and heparin binding EGF-like growth factor (HB-EGF),
collectively referred to as the EGF agonists (Mendelsohn, 2002).
A panel of antibodies with such inhibitory properties was devel-
oped 20 years ago by immunizing mice with human A431 epi-
dermoid carcinoma cells that express high levels of EGFR, se-
lecting antibodies that bind specifically to the extracellular
region of EGFR, and then screening for those that inhibit EGF
binding and receptor phosphorylation (Gill et al., 1984; Kawa-
moto et al., 1983; Sato et al., 1983). The resulting antibodies
inhibit cellular proliferation in vitro and in vivo (Masui et al.,
1984; Mendelsohn, 1988). For one of these antibodies, mAb
225, a human:murine chimeric version was produced (Goldstein
et al., 1995). This antibody, cetuximab (IMC-C225), marketed
under the name Erbitux, has been the center of intensive study
for its use as an anticancer agent (Graham et al., 2004) and
was approved by the FDA in February 2004 for use in treating
advanced-stage EGFR-expressing colorectal cancer.
Structural data published over the past few years have trans-
formed our view of how EGFR is regulated by ligand binding,. DOI 10.1016/j.ccr.2005.03.003 301
A R T I C L Eand have shed light on how agents that bind to the extracellu-
lar region of EGFR might inhibit EGFR activation (Figure 1)
(Burgess et al., 2003). EGFR dimerization is entirely receptor-
mediated, with no contacts between the two growth factor
molecules in the dimeric complex (Garrett et al., 2002; Ogiso
et al., 2002). By binding simultaneously to two sites (within do-
mains I and III) in the extracellular region of the receptor, growth
factor alters the spatial arrangement of the domains as shown
schematically in Figure 1. This domain rearrangement exposes
a critical region of domain II that is buried by an intramolecular
interaction (or tether) with domain IV in the inactive receptor
(Figure 1A). The region thus exposed is known as the dimeriza-
tion arm, and forms the core of the dimer interface in Figure
1D. Growth factors bind preferentially to the extended or un-
tethered forms of EGFR (Figure 1B) and “trap” the receptor in
the conformation that can dimerize through the exposed di-
merization arm (Figure 1C), thus driving the equilibrium shown
in Figure 1 to the right.
Based on this mechanism, there are several possible ways
that an inhibitor could bind to the extracellular region of EGFR
and prevent receptor activation. Such an agent could act as an
antagonist, and compete directly for ligand binding by interact-
ing with the growth factor binding sites on the receptor. Alter-
natively, the agent could block ligand binding indirectly by sta-
bilizing a receptor conformation that cannot bind growth factor
with high affinity. In addition, receptor dimerization and activa-
tion could be blocked by occluding the domain II dimerization
interface. The monoclonal antibody pertuzimab (2C4/Omnitarg)
functions in this way, binding to domain II of ErbB2 (HER2/neu)
and preventing its neuregulin-induced heterodimerization with
ErbB3 (Agus et al., 2002; Franklin et al., 2004).
Here we describe structural studies that reveal the molecular
mechanism of direct EGFR inhibition by the antibody drug cetux-
imab/Erbitux. A 2.8 Å resolution crystal structure of the cetux-
imab Fab fragment bound to the EGFR extracellular region
shows that the antibody binds to a site on domain III of theFigure 1. Mechanism of ligand-induced EGFR dimerization
The domains of the extracellular region of EGFR are shown in cartoon rep-
resentation, with domain I in red, domain II in green, domain III in gray with
red border, domain IV in gray with green border, and ligand in cyan. Most
(about 95%) of the unliganded EGFR exists in a compact autoinhibited or
tethered conformation, in which domains II and IV form an intramolecular
interaction or tether (A). In the remaining 5% of the unliganded molecules,
this tether is broken, and the sEGFR can adopt a range of untethered con-
formations (B), some of which will be more extended. Ligand binds prefer-
entially to untethered molecules, and interacts simultaneously with do-
mains I and III, stabilizing the particular extended form in which domain II
is exposed and the receptor can dimerize (C). Dimerization is entirely re-
ceptor-mediated and dominated by domain II interactions (D) (J.P. Daw-
son, M.B. Berger, C.-C. Lin, J. Schlessinger, M.A. Lemmon, and K.M.F., sub-
mitted).302receptor that overlaps the EGF binding site. In addition, cetux-
imab binding sterically prevents the EGFR extracellular region
from adopting the dimerization-competent extended configu-
ration depicted in Figures 1B–1D. These findings provide a
structural framework for improving agents that inhibit EGFR by
targeting its extracellular region.
Results and discussion
Binding of cetuximab to the soluble extracellular
region of EGFR
The entire extracellular region of EGFR (sEGFR), corresponding
to amino acids 1–618 of the mature protein with a C-terminal
hexa-histidine tag, was produced by secretion from baculovi-
rus-infected Sf9 cells exactly as described previously (Fergu-
son et al., 2000; Ferguson et al., 2003). The antigen binding
(Fab) fragment of cetuximab (FabC225) was prepared by pa-
pain digestion of the IgG protein. Using Surface Plasmon Res-
onance (SPR/Biacore), we found that sEGFR binds to immobi-
lized FabC225 (Figure 2A; black triangles) with a KD value of
2.3 ± 0.5 nM, similar to that observed for binding of the Fab
fragment of mouse mAb 225 to the EGFR in A431 cell homoge-
nates (Fan et al., 1993). Cetuximab also efficiently inhibits bind-
ing of sEGFR to immobilized EGF (Figure 2C). Addition of equi-
molar FabC225 to a 600 nM sample of sEGFR abolishes the
binding of sEGFR to immobilized EGF.
Structure determination
Crystals of the isolated Fab fragment of cetuximab that diffract
to 2.0 Å resolution were grown from 1.8 M ammonium sulfate,
100 mM sodium citrate at pH 6.25. The structure was solved
using molecular replacement (MR) methods with separate
search models for the variable (Fv) and the constant (Fc) do-
mains that were selected on the basis of sequence identity.
The final, refined model contained two FabC225 molecules in
the asymmetric unit. FabC225:sEGFR complex for crystalliza-
tion was prepared by mixing a 2-fold molar excess of purified
FabC225 with sEGFR, and separating the complex from ex-
cess Fab by size exclusion chromatography (SEC). Crystals of
the FabC225:sEGFR complex that diffract to 2.8 Å resolution
were grown from 15% PEG 3350, 250 mM (NH4)2SO4, 100 mM
imidazole, 10 mM CdCl2 (pH 7.5). The structure was solved
using MR methods with search models based on coordinates
of sEGFR (PDB id 1NQL) and FabC225. The final model, re-
fined to 2.8 Å resolution, contains amino acids 2–614 of
sEGFR, amino acids 1–211 of the Fab light chain, amino acids
1–220 of the Fab heavy chain, a total of 19 carbohydrate resi-
dues, and 71 ordered water molecules. Crystallographic and
refinement statistics are given in Table 1.
Conformation of sEGFR bound to cetuximab
Previously determined structures of dimeric and monomeric
sEGFR (Burgess et al., 2003) have shown that the individual
domains in the extracellular region are altered little (if at all)
upon binding of activating growth factor. Rather, the intramo-
lecular domain arrangement plays a primary role in the mecha-
nism of receptor activation. As expected, the structure of each
individual domain within FabC225-bound sEGFR is very similar
to that seen in monomeric sEGFR and in the sEGFR/ligand
complexes. The β helix or solenoid folds adopted by domains
I and III are rigid structures, and are not altered significantlyCANCER CELL : APRIL 2005
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sEGFR and inhibits sEGFR binding to EGF
A: Surface Plasmon Resonance (SPR) analysis of
sEGFR binding to immobilized FabC225. A series
of sEGFR samples of the indicated concentra-
tions or of the domain III fragment of sEGFR
(sEGFR-III) were passed over a Biosensor surface
to which FabC225 had been covalently cou-
pled. A representative data set of the equilib-
rium SPR response for each sample, expressed
as the fraction of the maximum binding, is plot-
ted as a function of the concentration of sEGFR.
The inset shows that no additional binding is
seen at higher concentrations. These data can
be fit to a simple one-site Langmuir binding
equation. The curve indicates the fit to the particular data set shown. KD values are the mean of at least three independent binding experiments. KD
values are 2.3 ± 0.5 and 1.7 ± 0.6 nM for sEGFR and sEGFR-III, respectively.
B: SPR equilibrium binding analysis, as described in A, of a similar set of samples of sEGFR and sEGFR-III to immobilized EGF. KD values are 130 ± 3 nM and
2.3 ± 0.5 M for sEGFR and sEGFR-III, respectively.
C: The ability of FabC225 to compete with immobilized EGF for sEGFR binding is shown. The indicated molar excesses of Fab were added to samples of a
fixed concentration of sEGFR (600 nM). The equilibrium SPR responses obtained by passing these mixtures over immobilized EGF, expressed as a fraction of
the response with no added Fab, are plotted as a function of the molar excess of Fab. Each data point is the mean of at least three independent
measurements. All binding is abolished at a 1:1 stochiometry of FabC225:sEGFR, and the IC50 value for these conditions is 500 nM.both contact the same ligand molecule, and the dimerizationThe domain arrangement seen in sEGFR bound to FabC225
Table 1. Data collection and refinement statistics
FabC225 FabC225:sEGFR complex
Data collection statisticsa
Space group P212121 P21
Unique cell dimensions a = 64.4 Å, b = 82.0 Å, c = 211.4 Å a = 77.8 Å, b = 70.9 Å, c = 147.1 Å; β = 102.5°
X-ray source NSLS X9A CHESS A1
Resolution limit 2.0 Å 2.8 Å
Observed/unique 635,708/73,414 143,424/38,621
Completeness (%) 95.6 (96.8) 98.9 (90.6)
Rsymb 0.07 (0.30) 0.05 (0.33)
<I/σ> 12.7 (5.5) 16.5 (5.6)
Refinement statistics
Resolution limits 15–2.0 Å 50–2.8 Å
No. of reflections/no. test set 70,346/3,588 36,547/1,931
R factor (Rfree)c 0.22 (0.27) 0.22 (0.27)
Model
Protein 2 FabC225 molecules 1 FabC225:sEGFR complex
aa 2–614 (sEGFR); 18 saccharide units
aa 1–213 (light chain) aa 1–211 (light chain)
aa 1–221 (heavy chain) aa 1–220 (heavy chain); 1 saccharide unit
353 water molecules 71 water molecules
Total number of atoms 7013 8152
RMSD bond lengths (Å) 0.012 0.013
RMSD bond angles (°) 1.76 1.66
aNumbers in parentheses refer to last resolution shell.
bRsym = Σ|Ih−<Ih>|/ΣIh, where <Ih> = average intensity over symmetry equivalent measurements.
cR factor = Σ|Fo−Fc|/ΣFo, where summation is over data used in the refinement; Rfree includes only 5% of the data excluded from the refinement.upon binding of growth factor or FabC225. Comparing the
structures of monomeric sEGFR with and without bound Fab,
the root mean square deviation (rmsd) for Cα positions is 0.93
and 0.54 Å for domains I and III, respectively. Similarly, domain
IV does not change significantly between these two structures
(rmsd of 1.0 Å for Cα positions), nor does the relative orienta-
tion of domains III and IV. As discussed in more detail later, the
conformation of domain II does differ between the two sEGFR
structures—probably as a result of crystal packing.CANCER CELL : APRIL 2005is similar to that previously observed for monomeric sEGFR
(Ferguson et al., 2003) and for sErbB3 (Cho and Leahy, 2002)
(Figure 3A). This conformation is characterized by an intramo-
lecular interaction between domains II and IV that “tethers” the
molecule in an autoinhibited conformation that is distinct from
the extended conformation observed in the dimeric complexes
of sEGFR with EGF (Ogiso et al., 2002) and with TGFα (Garrett
et al., 2002). In the tethered conformation, the ligand binding
sites on domains I and III are too distant from one other to303
A R T I C L EFigure 3. Cetuximab binds to domain III of a tethered sEGFR molecule
A: Ribbons representation of FabC225:sEGFR complex. The VL chain of FabC225 is shown in yellow, the VH chain in orange, domain I of sEGFR in red, and
domain II in green. Domains III and IV are in gray, with the edges of the secondary structure elements in red and green, respectively. The box indicates
the area of detail shown in B.
B: Closeup view of the FabC225:sEGFR interface. The CDRs are colored yellow for the VL chain and orange for the VH chain, and the remainder of the
FabC225 is colored gray. Side chains that make key interactions are shown. Amino acid labels are colored orange for the VH of FabC225, black on a
yellow background for FabC225 VL, and black on a white background for sEGFR. Hydrogen bonds are indicated with a dashed gray line.interface on domain II is occluded by the intramolecular
tether interaction.
The previously described structure of tethered sEGFR was
obtained using crystals that were grown at pH 5.0, and that
contained an EGF molecule bound weakly to the domain I li-
gand binding site (Ferguson et al., 2003). The structure de-
scribed here represents the first structure of sEGFR with no
bound growth factor ligand and at neutral pH. The common
tethered configuration observed in these two sEGFR structures
supports our previous conclusion that this tethered sEGFR
configuration is the predominant unliganded form of the recep-
tor (Ferguson et al., 2003). Further, since cetuximab is an inhib-
itor of EGFR, this also strengthens our conclusion that the teth-
ered form represents an inactive state of the EGFR extracellular
region. Minor differences in the arrangement of the domains in
the two tethered structures of sEGFR are discussed below.
The cetuximab binding site on sEGFR
The cetuximab Fab fragment binds exclusively to domain III,
covering an epitope that partially overlaps the growth factor
binding site on that domain (see below). Both the heavy and
the light chains of cetuximab participate in the interaction with
domain III, with all contacts coming from the complementarity
determining regions (CDRs) of FabC225 (Figure 3B). CDRs L3
and H3 contribute the majority of the interactions with the re-
ceptor, and there are additional contributions from CDRs L1
and H2. Such a distribution of interactions is common in anti-
body-antigen complexes (Sundberg and Mariuzza, 2002). The
binding surface of FabC225 is rich in tyrosines and trypto-
phans, as is also typical for antibody combining sites (Lo Conte
et al., 1999). A total of 882 Å2 of solvent accessible surface
area on domain III is buried by FabC225 (a similar area is oc-
cluded from solvent on the Fab so that the total solvent acces-304sible surface buried on formation of the FabC225:sEGFR com-
plex is 1770 Å2). Approximately two-thirds of the buried surface
area on domain III is occluded from solvent by the heavy chain
of FabC225. The overall shape complementarity (sc) parameter
for the FabC225:sEGFR interface is 0.71 (Lawrence and Col-
man, 1993). This is larger than typically observed for an anti-
body-antigen binding interface (Lawrence and Colman, 1993),
but is similar to that observed for the interaction of sErbB2 with
both trastuzumab (Cho et al., 2003) and pertuzumab (Franklin
et al., 2004). A higher sc parameter correlates with a higher-
affinity antibody-antigen interaction (Li et al., 2003) and is thus
expected for antibody drugs that have been selected, in part,
for tight binding to their target.
The conformation of FabC225 is not altered significantly
upon sEGFR binding. The backbone conformations of bound
and unbound FabC225 are very similar (rmsd for Cα positions
of VL is 0.45 Å, and for VH is 1.1 Å), and there is only a small
(15°) decrease in the elbow angle in the bound structure. Nota-
bly, the conformations of the CDRs of FabC225 are essentially
identical with and without bound sEGFR.
The light chain of FabC225 interacts with the C-terminal re-
gion of domain III. Q27 at the tip of CDR L1 makes the only
side chain to side chain hydrogen bond between VL and the
receptor, interacting with N473 at the beginning of the C-ter-
minal helix of domain III (Figure 3B). An extensive network of
intermolecular main chain hydrogen bonds between CDR L3
and the most C-terminal strand of the domain III β helix con-
tributes most of the light chain interactions, and serves to posi-
tion the side chain of W94 of CDR L3 to interact with the ali-
phatic portion of K443 on the adjacent strand from the domain
III β helix. CDR L2 contributes little to the interaction, although
the side chain of Y50 makes a small contribution to the hy-
drophobic pocket that surrounds I467 from the receptor.CANCER CELL : APRIL 2005
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and sEGFR come from the CDRs H2 and H3. At the center of
the interface is a tyrosine from CDR H3 (Y102) that protrudes
into a hydrophobic pocket on the surface of the large β sheet
of domain III (see Figures 3B and 4), its hydroxyl group ideally
placed to make hydrogen bonds with two glutamine side
chains from sEGFR (Q384 and Q408). CDRs H2 and H3 of
FabC225 are anchored over this hydrophobic pocket on do-
main III by a series of interactions that include two salt bridges
(D58[VH] to K443[sEGFR] and D103[VH] to K465[sEGFR]), two
further side chain to side chain hydrogen bonds (W52[V ] toFigure 4. The cetuximab epitope partially overlaps the ligand binding region on domain III
A: The binding site region of the FabC225:sEGFR complex with domains colored as in Figure 2. The central Y102 from CDR H3 is shown, as are the side
chains on sEGFR that contribute to the hydrophobic binding (ringed in black). Q27 from CDR L1 and N473 from sEGFR that form a direct hydrogen bond
are also shown. The sEGFR:EGF complex is shown with domain III in the same orientation. Domains I and II of sEGFR are not drawn so that the ligand
binding region can be seen. L47 of EGF occupies the same binding pocket as Y102 of FabC225 (ringed in black). R41 from EGF and D355 from sEGFR that
make a critical salt bridge are also shown.
B: Detailed view of the interactions of domain III of sEGFR with FabC225 and with EGF. The view is looking down onto the binding site (90° rotation about
the indicated axis). Only those parts of FabC225 and EGF that are directly involved in binding to this domain are shown. Side chains from FabC225 and
EGF that interact with sEGFR are labeled in black. The same set of side chains on the sEGFR are shown in both panels. Where these residues are involved
in interaction, they are colored pink and marked with red labels. Hydrogen bonds are shown with dotted black lines. Key water molecules are shown as
green spheres.H
CANCER CELL : APRIL 2005S418[sEGFR] and Y104[VH] to S468[sEGFR]), two side chain-
to-main chain hydrogen bonds (between the G54 and D103
carbonyl oxygens from VH and the S440 and R353 side chains
from sEGFR), plus indirect hydrogen bonds linking N56(VH)
with S418 and Q384 from EGFR through two highly ordered
water molecules (Figures 3B and 4B). Such water-mediated hy-
drogen bonds are common in antibody-antigen interactions
(Sundberg and Mariuzza, 2002), and there are likely more or-
dered waters in this interface that cannot be modeled with any
confidence at the resolution of this structure.
As described above, all of the interactions between the ce-305
A R T I C L Etuximab Fab and sEGFR are with domain III of the receptor,
with no interactions to domain I, or indeed domains II or IV.
To confirm that only domain III is required for the high-affinity
interaction of FabC225 with sEGFR, we generated recombi-
nant baculovirus to direct expression and secretion from Sf9
cells of isolated domain III (amino acids 310–514 of mature
EGFR). As shown in Figure 2A (red points and curve) the affinity
of isolated domain III for immobilized FabC225 is the same as
that observed with full-length sEGFR. By contrast, the binding
of isolated domain III to EGF is substantially weaker than for
full-length sEGFR (Figure 2B), as previously reported for a pro-
teolytically derived sEGFR fragment that encompasses domain
III (amino acids 302–503) (Kohda et al., 1993; Lemmon et al.,
1997). Whereas high affinity binding of growth factor ligand re-
quires both domains I and III of sEGFR, cetuximab Fab effi-
ciently blocks growth factor binding through high-affinity in-
teraction with domain III alone.
Comparison of sEGFR binding sites
for cetuximab and EGF/TGF
Figure 4 compares the interfaces formed by domain III with
FabC225 and EGF, respectively, and illustrates how the binding
site for the cetuximab Fab partially overlaps the domain III EGF
binding site (Garrett et al., 2002; Ogiso et al., 2002). Y102 on
CDR H3 of FabC225 occupies approximately the same posi-
tion on the surface of sEGFR (ringed in Figure 4A) as does an
essential leucine side chain from the growth factor (L47 in EGF,
L48 in TGFα). Both EGF and TGFα pack more deeply into the
binding pocket in this region of sEGFR than FabC225. The
packing for FabC225 is augmented by two side chain hy-
drogen bonds between the Y102 hydroxyl and glutamines on
sEGFR (Q384 and Q408). By contrast, there are no side chain
to side chain hydrogen bonds in this region when growth
factors bind sEGFR. The only side chain to side chain interac-
tion that occurs with domain III in the growth factor complexes
is a salt bridge between an arginine on the ligand (R41 in EGF
and R42 in TGFα) and an aspartate (D355) near the N-terminal
part of the domain III β helix. There are no contacts between
FabC225 and this region of domain III. Rather, as described
above, FabC225 makes additional contacts with the C-terminal
end of domain III that are not part of the EGF binding site, as
shown in Figure 4.
The affinity of the FabC225:sEGFR interaction is 3 orders of
magnitude higher than that for interaction of EGF with isolated
domain III, and 50-fold greater than for the interaction between
EGF and full-length sEGFR (where domain I also contributes).
It is not immediately clear from the crystal structures what is
the origin of the approximately 4.5 kcal/mol additional binding
energy for FabC225 binding to domain III of sEGFR relative to
the interaction of the growth factor ligands. A larger buried sur-
face area is often associated with a stronger interaction (Lo
Conte et al., 1999), and the surface area of domain III that is
buried by FabC225 is larger than that buried by the growth
factors (882 Å2 for FabC225 versus 810 Å2 and 729 Å2 for EGF
and TGFα, respectively; see Table 2). However, the additional
buried surface area is largely polar, and the total apolar buried
surface area on domain III in the FabC225:sEGFR complex is
actually less than that for EGF or TGFα binding. Thus, the
larger buried surface area does not provide a simple explana-
tion for the increase in binding energy. This contrasts with a
recent study that compared a series of antibodies with differing306Table 2. Comparison of interaction of domain III of sEGFR with FabC225, EGF,
and TGFα
FabC225: sEGFR: sEGFR:
sEGFR EGFa TGFαa
Number of hydrogen bonds (%3.5 Å)b 10 5 5
Salt bridge interactions 2 1 1
Area of domain III buried by ligand (Å2)c 882 810 729
Polar area 440 299 248
Apolar area 442 511 481
Shape complementarity 0.71 0.70 0.70
aValues are for the interaction between chains A (sEGFR) and C (EGF/TGFα).
Values are similar for the other complex.
bDefined using the program HBPLUS (McDonald and Thornton, 1994).
cThe total surface area buried in the complex is approximately twice this value
since an almost equal area of surface on the FabC225 also becomes solvent-
inaccessible in the complex.affinities for the same epitope on hen egg white lysozyme (Li
et al., 2003). In this study, higher affinity of the antibody for the
antigen tracked with an increase in the proportion of apolar
buried surface area. The interface between the growth factor
ligands and domain III is more apolar (z65%) than typically
observed in this type of protein-protein interaction, yet is of
rather low affinity. The proportion of polar surface (z50%) bur-
ied in the FabC225:sEGFR is typical for a high-affinity antigen-
antibody interaction (Li et al., 2003; Lo Conte et al., 1999). The
shape complementarity (sc) parameter for the interaction of
FabC225 with sEGFR is quite high for an antibody-antigen in-
teraction, and is similar to that for the interaction of EGF and
TGFα with domain III of sEGFR.
As would be expected in a more polar interface, there are a
greater number of hydrogen bonds between FabC225 and do-
main III of sEGFR than observed for the growth factor com-
plexes (Table 2). There is no simple correlation between the
number of hydrogen bonds or salt bridges in a protein-protein
interaction and the observed affinity of a complex. Due to the
large energy associated with desolvation of charged and polar
groups at the interface upon formation of a protein-protein
complex, these interactions are typically considered unfavor-
able (Honig and Nicholls, 1995) and are more usually consid-
ered to define specificity. In some cases, however, polar and
charged interactions can contribute significantly to the binding
energy (Sheinerman et al., 2000). Two features that have been
pointed out as indicators of stabilizing charged and polar in-
teractions (Sheinerman and Honig, 2002) are observed in the
interaction of FabC225 and sEGFR. As can be seen in Figure
4B, the hydrogen bonds in the interface form a network that is
likely even more extensive with the participation of ordered
water molecules that cannot be modeled with accuracy at the
resolution of this structure. Such networks stabilize charged
and polar interactions. The second issue relates to the struc-
ture of free antibody. Two aspartates (D58 and D103) that par-
ticipate in salt bridges in the FabC225:sEGFR complex are par-
tially buried in the free antibody structure, which will reduce the
energy required to desolvate these charged groups, resulting
in a potentially higher contribution of these salt bridges to the
strength of the interaction.
As discussed above, neither the structure of the antibody
nor the structure of domain III changes upon binding. By con-
trast, the growth factor ligands appear to be quite flexible. InCANCER CELL : APRIL 2005
A R T I C L Ethe crystal structure of isolated EGF there are two molecules
in the asymmetric unit that each adopt a different conformation
(Lu et al., 2001). Similarly, NMR structures of EGF (Cooke et
al., 1987; Montelione et al., 1987) and TGFα (Kline et al., 1990;
Tappin et al., 1989) suggest that regions involved in interaction
with sEGFR are quite disordered. A disorder to order transition
in the ligand upon binding to sEGFR may be one origin of their
weaker affinity for sEGFR relative to binding of the antibody,
rather than any difference in the nature of the interactions with
domain III. It should be noted that this consideration may sug-
gest that useful (flexible) antagonistic ligand analogs are un-
likely to emerge.
Mutations in domain III differentially affect the binding
of sEGFR to EGF and to cetuximab Fab
To confirm that the C225 epitope observed in the crystal accu-
rately reflects that seen in solution, we generated mutations in
two regions on the face of the large β sheet of domain III (Figure
5), in an effort to selectively impair EGF binding, antibody bind-
ing, or both. Substitution of the aspartic acid at position 355
with threonine, and of the phenylalanine at position 357 with
alanine, has no effect on binding of sEGFR to immobilized
FabC225 (as expected, since these amino acids are not part
of the cetuximab epitope). However, as expected, since these
side chains are involved in binding to growth factor ligand, this
sEGFR variant binds immobilized EGF more than 100-fold
more weakly than wild-type sEGFR (Figures 5B and 5C). By
contrast, mutations in the region near the hydrophobic pocket
that accommodates the leucine side chains of the growth
factor ligand and the tyrosine 102 of the FabC225 disrupt bind-
ing of sEGFR to both FabC225 and EGF. A double mutant
Q408M/H409E shows a 150-fold reduction in FabC225 bind-
ing, but only a 3.5-fold decrease in EGF binding. Additional
alteration of Q384A results in a z1 M KD in both cases (Fig-
ure 5).Figure 5. Mutational analysis of cetuximab epitope on sEGFR
A: A solvent-accessible surface representation of domain III in the same orientation as in Figure 4B. The surface is colored according to whether it interacts
with EGF only (blue), FabC225 only (yellow), or both (green). The positions of the side chains shown in Figure 4B are indicated. The amino acids altered for
the binding studies in B are shown in red.
B: Binding of altered sEGFR to immobilized FabC225. Data are presented as described in Figure 2A. In each case, the SPR response is expressed as a
fraction of the maximum response for wild-type sEGFR.
C: Binding of the same sEGFR samples to immobilized EGF.CANCER CELL : APRIL 2005Comparison of domain II conformation
in sEGFR structures
As mentioned above, the structures of domains I and III do not
change upon binding of growth factor or antibody, and domain
IV is unaffected by FabC225 binding. However, alterations in
domain II are detected when the different sEGFR structures are
compared, and these warrant some comment. Differences in
domain II conformation result in a change in the relative orien-
tations of domains I and III when the tethered sEGFR structure
reported here is compared with the previously published pH 5
structure (Ferguson et al., 2003). With respect to domain III, the
position of domain I in the two structures differs by a 50° rota-
tion around an axis that is approximately parallel to the long
axis of the domain II dimerization arm. This difference is not
caused by the EGF that is weakly bound to domain I in the pH
5.0 tethered structure: an EGF molecule can easily be accom-
modated at the domain I binding site in the FabC225:sEGFR
structure. Rather, we suggest that these structures provide two
snapshots of a flexible domain II, which have been trapped by
different crystal packing environments. An overlay of domain II
from each crystal structure of sEGFR and of sErbB3 is shown
in Supplemental Figure S1. The differences in the conformation
of domain II in the two tethered structures lie almost entirely in
the N-terminal half of this domain. By contrast, the conforma-
tion of the C-terminal half of domain II is similar for each teth-
ered structure but distinct from the conformation of this region
of domain II in the dimeric structures.
Influence of cetuximab on the conformation of sEGFR
Although cetuximab does not affect the structure of the indivi-
dual domains in sEGFR, its binding to the tethered state of
sEGFR will influence the distribution of conformations that are
accessible to sEGFR. For unliganded sEGFR, some 5% of the
receptors are estimated to be untethered and to adopt a range
of extended conformations (Burgess et al., 2003; Ferguson et307
A R T I C L Eal., 2003). Cetuximab binding to domain III restricts the range
of extended conformations available to this untethered popula-
tion of receptors. Most importantly, the extended conformation
that is required for dimerization is inaccessible to FabC225-
bound sEGFR. By superimposing domain III from the
FabC225:sEGFR complex with domain III from the sEGFR:EGF
complex (Ogiso et al., 2002), it is apparent that FabC225 not
only overlaps with the bound EGF but also with parts of do-
main I (Figure 6). With cetuximab bound to EGFR, the VH region
of the antibody sterically blocks domain I from occupying the
position observed in the ligand-bound structures which, in
turn, prevents domain II from adopting the conformation re-
quired for dimerization. Since the receptor cannot adopt the
conformation and location required for high-affinity ligand bind-
ing, it is also less likely that excess ligand could displace the
bound antibody.
Implications for the mechanism of inhibition of EGFR
by cetuximab
The structure presented here illustrates how cetuximab pre-
vents ligand binding to EGFR, inhibits receptor dimerization,Figure 6. Cetuximab prevents sEGFR from adopting the extended conformation
A: One molecule from the sEGFR:EGF dimer is shown, with domains colored as in Figure 3 and EGF in cyan. Domain III from the FabC225:sEGFR complex
was superimposed on domain III from this sEGFR:EGF complex. Only the FabC225 from the FabC225:sEGFR complex is shown, with colors as in Figure 3. A
portion from the VH domain of FabC225 (orange) clashes with EGF and with domain I from the sEGFR:EGF complex.
B: The VH region of FabC225 is shown in space-filling representation to highlight the steric clash that would occur between this part of FabC225 and the
N-terminal portion of domain I.
C: Model for inhibition of ligand-induced dimerization by cetuximab. In addition to blocking the domain III ligand binding site, FabC225 prevents the
receptor from adopting the extended conformation required for high-affinity ligand binding and dimerization.308and thus blocks EGFR autophosphorylation and activation.
This is believed to be the critical factor in the observed antitu-
mor effects of this antibody in vivo (Mendelsohn and Baselga,
2003). The primary consequence of cetuximab binding to
EGFR is to sterically block access of the growth factor to a key
ligand binding region on domain III of the receptor. The ligand
binding site on domain I is unaffected, but growth factor must
engage sites on both domains I and III for high-affinity binding
that activates the receptor, so efficient blockade of either one
is sufficient to debilitate the receptor.
It is also clear from the structure that the EGFR extracellular
region cannot adopt the extended dimerization-competent
configuration depicted in Figures 1C and 1D while cetuximab
remains bound. As mentioned above, steric clashes between
the Fab and domain I will prevent this. Since ligand binding is
normally required for the EGFR extracellular domain to adopt
this extended configuration, and ligand binding is directly
blocked by cetuximab, the importance of this conformational
restriction for the inhibitory effects of the antibody is not imme-
diately clear. However, the possibility remains that EGFR may
under some circumstances be activated through mechanismsCANCER CELL : APRIL 2005
A R T I C L Ethat involve stabilization of the extended configuration without
ligand binding, through homo- or heterodimerization with other
activated ErbB receptor molecules (Sawano et al., 2002; Ver-
veer et al., 2000). Cetuximab binding will prevent this potential
mode of activation, which may be relevant under conditions of
receptor overexpression.
While direct inhibition of EGFR activation is considered the
primary mechanism for the antitumor activity of cetuximab in
vivo, additional mechanisms such as antibody-dependent cel-
lular cytotoxicity (ADCC) and receptor internalization are also
likely to play an important role. Indeed, the monovalent Fab
fragment, which can elicit neither of these responses, is less
effective than the bivalent mAb in inhibiting proliferation of cul-
tured cells (Fan et al., 1993; Fan et al., 1994), although it is not
without significant inhibitory effect. It is interesting to note that
the intracellular fate of internalized cetuximab:EGFR com-
plexes is likely to be different from that of growth factor:EGFR
complexes. Whereas EGF binding is almost completely abol-
ished at endosomal pH levels of w5 (Ferguson et al., 2003),
cetuximab binding to sEGFR is unchanged when the pH is re-
duced from pH 7 to pH 5 (data not shown). Thus, cetuximab
is not likely to dissociate from the receptor in the low pH envi-
ronment of the endosome, and the complex will be targeted
for lysosomal degradation.
The structure of cetuximab in complex with sEGFR de-
scribed here has implications for the design of small molecule
agonists of EGFR. Attempts to block EGFR activation with an-
tagonistic ligand analogs have not yet proven fruitful (Groenen
et al., 1994; Matsunami et al., 1990). As described above, this
may be due to the inherent flexibility of the ligand. A peptide
with a more rigid scaffold that can mimic the high-affinity in-
teraction of cetuximab with sEGFR may be more successful as
an inhibitor than a simple ligand analog. Further, if such a mole-
cule is fused to a bulky moiety that can sterically prevent the
receptor from adopting the extended conformation, this could
enhance the potency of the inhibitor. The definition of the epi-
tope for cetuximab also serves as a focus to screen for somatic
mutations in EGFR that may lead to an increased (or de-
creased) sensitivity to this EGFR-targeted drug. Somatic mu-
tations in the kinase domain of EGFR have recently been
correlated with the sensitivity of certain lung cancers to the
EGFR-specific tyrosine kinase inhibitor (TKI) gefitinib (Lynch et
al., 2004; Paez et al., 2004; Pao et al., 2004). Finally, it will be
interesting to establish whether other anti-EGFR antibodies
that are currently in clinical trials share a common epitope to
that of cetuximab.
Experimental procedures
Protein expression and purification
sEGFR was produced and purified from baculovirus-infected Sf9 cells ex-
actly as described (Ferguson et al., 2000), and was used without modifi-
cation of its glycosylation state. This sEGFR was further purified by size
exclusion chromatography (SEC) using a SEC250 column (BioRad) pre-
equilibrated with 25 mM HEPES, 100 mM NaCl (pH 7.5). To produce iso-
lated domain III of sEGFR (sEGFR-III), recombinant baculovirus was gener-
ated to direct expression of amino acids 310–514 of the mature EGFR
extracellular region, plus a C-terminal hexahistdine tag, fused to the native
signal peptide of EGFR. The sEGFR-III was expressed and purified exactly
as for full-length sEGFR. The Fab fragment of cetuximab (FabC225) was
prepared by treatment of the IgG protein with papain. The IgG protein (20
mg/ml) was incubated with papain (1:1000 w:w) at 37°C for one hour and
the reaction stopped with iodoacetemide (75 mM final concentration). Un-CANCER CELL : APRIL 2005digested mAb and Fc fragments were removed by passing the mixture
over a Protein-A column. The flowthrough from this column, containing
FabC225, was used for crystallization of the Fab alone without further purifi-
cation. To make FabC225:sEGFR complex, FabC225 was first purified on a
SEC250 column exactly as for sEGFR. The FabC225 containing fractions
were concentrated and mixed with sEGFR to give a 2-fold molar excess of
Fab, and FabC225:sEGFR complex was separated from excess Fab using
the same SEC column. Fractions containing the FabC225:sEGFR complex,
as confirmed by SDS-PAGE, were concentrated to 11 mg/ml.
Crystallization and data collection
For crystallization of FabC225 alone, the flowthrough from the Protein-A
column was buffer-exchanged into 100 mM NaCl, 10 mM Tris (pH 8.5), and
adjusted to 22 mg/ml. Crystals were obtained by the vapor diffusion
method. Equal volumes of FabC225 solution were mixed with a solution
containing 1.8 M ammonium sulfate, 100 mM sodium citrate at pH 6.25,
and equilibrated over a reservoir of this solution. Large single crystals were
cryostabilized by rapid stepwise equilibration in solutions of reservoir con-
taining increasing concentrations of glycerol (10%, 20%, and 30% volume/
volume) and were flash frozen in liquid nitrogen. Data were collected at the
National Synchrotron Light Source (NSLS) beamline X9A, using a MAR 165
CCD detector, and were processed using HKL (Otwinowski and Minor,
1997).
The purified FabC225:sEGFR complex was buffer-exchanged into 25 mM
HEPES (pH 7.5), containing 50 mM NaCl, and was crystallized by the hang-
ing drop vapor diffusion method from a drop containing equal parts of a 78
M FabC225:sEGFR complex solution and reservoir solution of 15% PEG
3350, 250 mM (NH4)2SO4, 100 mM Imidazole, 10 mM CdCl2 (pH 7.5). Streak
seeding was used to produce large (0.08 × 0.08 × 0.6 mm) single crystals.
Crystals were cryostabilized with a brief exposure to 15% PEG 3350, 15%
Ethylene Glycol, 250 mM (NH4)2SO4, 100 mM Imidazole, 10 mM CdCl2 (pH
7.5), and were flash frozen in liquid nitrogen. Data were collected at the
Cornell High Energy Synchrotron Source (CHESS) beamline A1, using an
ADSC Quantum-210 CCD detector, and were processed using HKL2000
(Otwinowski and Minor, 1997).
Structure determination and refinement
Coordinates of the FabC225 and the FabC225:sEGFR structures have been
deposited with the RCSB protein data bank (PDB id codes 1YY8 and 1YY9,
respectively). The structure of the FabC225 was solved by molecular re-
placement (MR) methods using the program AMORE (CCP4, 1994). Sepa-
rate search models were selected for the variable (Fv) and constant (Fc)
regions on the basis of sequence identity, the Fv region of the antibody 40-
50 (PDB id 1IBG) (Jeffrey et al., 1995), and the Fc region from the human
antibody Ctm01 (PDB id 1AD9) (Banfield et al., 1997). Both molecules in
the asymmetric unit were located. The model was rebuilt using O (Jones et
al., 1991) and refined using CNS (Brunger et al., 1998).
To solve the FabC225:sEGFR complex, search models for MR were de-
rived from the coordinates of tethered sEGFR (PDB id 1NQL) and of the
structure of FabC225 alone. An initial solution was found for a domain I/II
fragment (amino acids 5–240) combined with a domain III fragment of
sEGFR using the dyad option of MOLREP (CCP4, 1994) to search for the
best relative orientation of these two fragments. With the solution for these
fragments fixed, a solution for the Fab fragment was found. Rigid body
refinement with CNS was used to optimize the orientation of the individual
subdomains of FabC225. Following several rounds of model building using
O (Jones et al., 1991) and refinement using CNS (Brunger et al., 1998),
interpretable density for the remaining portions of sEGFR (C-terminal part
of domain II and domain IV) could be seen in composite simulated-anneal-
ing omit-maps (calculated with CNS). The final stages of refinement em-
ployed TLS refinement (Winn et al., 2001) with anisotropic motion tensors
refined for each of the four domains of sEGFR and each domain of
FabC225, using REFMAC5 (CCP4, 1994).
Generation of binding site sEGFR mutations
Standard PCR-directed mutagenesis strategies were used to produce the
appropriate DNA in the pFastBac vector. Targeted residues were mutated
to the corresponding amino acid found at that position in Drosophila EGFR
(DER), or to alanine if the position in DER was conserved (DER does not
bind to human EGF or to cetuximab). The following mutations were made:309
A R T I C L EQ384A, Q408M/Q409E, Q384A/Q408M/Q409E, and D335T/F357A. The
generation of baculovirus and overexpression and purification of the pro-
teins in Sf9 cells were exactly as reported for wild-type sEGFR (Ferguson
et al., 2000).
Binding studies
Surface plasmon resonance (SPR) binding experiments were performed on
a BIAcore 3000 instrument at 25°C in buffer containing 10 mM HEPES
buffer (pH 8.0), 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20 (HBS-
EP8). EGF-agonists (200 g/ml) were coupled to a CM5 BIAcore sensor
chip using standard amine coupling. Optimal coupling was obtained in 10
mM sodium acetate at pH 4.0 for EGF and TGFα. Binding of sEGFR to
these immobilized ligands was performed and analyzed exactly as de-
scribed (Ferguson et al., 2000). FabC225 was coupled to a separate sensor
chip using amine coupling. FabC225 was diluted to 50 g/ml in 10 mM
sodium acetate at pH 5.5 and passed over the activated surface for 5 min
at a flow rate 10 l/minute. The binding of sEGFR to this surface was deter-
mined exactly as for sEGFR binding to immobilized EGF with the following
modifications: a longer contact time was used (10 l/min for 25 min; 250
l injection) to ensure that equilibrium was reached in binding of sEGFR to
the surface even at low concentration, and the surface was regenerated
between data points with two 5 l injections of 10 mM glycine (pH 2.5), 1 M
NaCl to rapidly remove residual bound sEGFR. This regeneration did not
impair the binding of sEGFR to FabC225; the observed response for a con-
trol sEGFR sample is constant over multiple cycles of binding and regenera-
tion. The effect of added FabC225 upon the binding of sEGFR to immobi-
lized ligand was determined using the ligand chip described above. Binding
was measured for a series of samples containing 600 nM sEGFR and
increasing molar excesses of FabC225. Data were analyzed using Prism 4
(GraphPad Software, Inc.).
Supplemental data
Supplemental Figure S1 can be found at http://www.cancercell.org/cgi/
content/full/7/4/301/DC1/.
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